scholarly journals Water exchange method for colonoscopy: Learning curve of an experienced colonoscopist in a U.S. community practice setting

2012 ◽  
Vol 2 (3) ◽  
pp. 128-132 ◽  
Author(s):  
Leonard S. Fischer ◽  
Antoinette Lumsden ◽  
Felix W. Leung
2008 ◽  
Vol 26 (33) ◽  
pp. 5335-5343 ◽  
Author(s):  
Hansjochen Wilke ◽  
Robert Glynne-Jones ◽  
Josef Thaler ◽  
Antoine Adenis ◽  
Peter Preusser ◽  
...  

Purpose This large, multinational study aimed to confirm in a community practice setting the efficacy and safety of cetuximab plus irinotecan in patients with epidermal growth factor–expressing metastatic colorectal cancer (mCRC) who had recently failed an irinotecan-containing regimen. Patients and Methods The primary objective was to determine the progression-free survival (PFS) rate at 12 weeks. The initial cetuximab dose was 400 mg/m2 and was followed weekly by 250 mg/m2; irinotecan (according to prestudy regimen) was given weekly (125 mg/m2 weekly for 4 of 6 weeks), every 2 weeks (180 mg/m2 each), or every 3 weeks (350 mg/m2 each). Results The intention-to-treat/safety population comprised 1,147 treated patients who received irinotecan weekly (n = 93); every 2 weeks (n = 670); every 3 weeks (n = 356); or another dose (n = 28). The PFS rate at 12 weeks was 61%, and the median survival was 9.2 months. Treatment was generally well tolerated. The most common treatment-related grades 3 to 4 adverse events were diarrhea (19%), neutropenia (10%), rash (7%), and asthenia (6%). The rate of grades 3 to 4 infusion-related reactions (IRRs; composite adverse event category) was 1% for patients who received both antihistamine and corticosteroid premedication. Conclusion Tolerability (except IRR incidence), PFS rate, and overall survival rate were in line with previous results. At 1%, the rate of IRRs in patients who received prophylactic premedication with both antihistamine and corticosteroid is lower than previously reported. MABEL clearly confirms in a community practice setting the efficacy and safety of cetuximab plus irinotecan in the treatment of mCRC.


2006 ◽  
Vol 45 (7) ◽  
pp. 649-654 ◽  
Author(s):  
Marlene Goodfriend ◽  
Thomas Bryant ◽  
William Livingood ◽  
Jeffrey Goldhagen

ChemPhysChem ◽  
2013 ◽  
Vol 14 (11) ◽  
pp. 2589-2593 ◽  
Author(s):  
Minghuan Liu ◽  
Wanchen Zhao ◽  
Shuo Wang ◽  
Wen Guo ◽  
Yuzhao Tang ◽  
...  

Author(s):  
Makoto Arai ◽  
Humberto S. Makiyama ◽  
Liang-Yee Cheng

In recent years, ballast water has been blamed for a variety of marine pollution problems, particularly for transporting harmful aquatic organisms from one part of the world to another and damaging the ecosystem of the new areas. A relatively simple mechanism to control this problem is to exchange ballast water on the high seas between ports in order to remove invasive species before the ship reaches its destination. However, some issues regarding ballast exchange on the open sea need to be addressed before this operation is introduced. One of them is the sloshing of the sea water in the ballast tank. In this paper, ballast water exchange on the open sea by means of the Sequential exchange method is simulated. Irregular seaways are generated from the ISSC spectrum, and the sloshing response of the water in the ballast tanks of a large merchant ship is numerically computed by using a finite difference code developed by the authors. The results showed that there is little possibility that severe sloshing presents a serious problem in regard to the ballast tank’s strength, especially in the case of a bulk carrier whose tanks are generally short in length, with sloshing anticipated only at the low water level.


2018 ◽  
Vol 132 (5) ◽  
pp. 1121-1129 ◽  
Author(s):  
Mark S. DeFrancesco ◽  
Richard N. Waldman ◽  
Melissa M. Pearlstone ◽  
Dana Karanik ◽  
Ryan Bernhisel ◽  
...  

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 739A
Author(s):  
Elif Küpeli ◽  
Pinar Seyfettin ◽  
Merih Demirel

Sign in / Sign up

Export Citation Format

Share Document